A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
Saved in:
| Title: | A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers. |
|---|---|
| Authors: | Fujita R; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Blot V; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Wong E; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Stewart C; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Lieuw V; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Richardson R; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Banah A; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Villicana J; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Timmer A; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Coronella J; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Newman R; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA., Gymnopoulos M; Research Department, Tanabe Research Laboratories U.S.A., Inc, San Diego, CA, USA. |
| Source: | Cancer biology & therapy [Cancer Biol Ther] 2020 Jun 02; Vol. 21 (6), pp. 549-559. Date of Electronic Publication: 2020 Mar 19. |
| Publication Type: | Comparative Study; Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
